A fast, costless nutritional mouse model, to rapidly evaluate your compounds targeting (NASH)

**Key benefits**

- **Get a deep evaluation** (biochemistry, histology and NAS score) of your compounds targeting NASH within 2 months.
- 1 week diet-induction and 2 weeks treatment to evaluate the impact of your drug vs. benchmark:
  Our unique nutritional model develops NASH features like high ALT/AST levels, increased liver lipids, severe inflammation, perisinusoidal fibrosis within 3 weeks.

**ANIMAL MODEL**

- Background strain: C57BL/6J mouse
- In-house Ultra-fast NASH diet: 60% high fat diet supplemented with cholesterol/cholic acid (HFCC)+cyclodextrin in drinking water (HFCC+CDX)
- Study duration: 3 weeks
- Reference compounds: ezetimibe (intestinal cholesterol absorption inhibitor), liraglutide (GLP-1 receptor agonist)

**CHARACTERISTICS AFTER 2 WEEKS TREATMENT**

**EZETIMIBE REDUCES HYPERLIPIDEMIA AND IMPROVES NAS SCORING THROUGH REDUCED INFLAMMATION**

- Ezetimibe reduces hyperlipidemia and improves NAS scoring through reduced inflammation.
- *p<0.05, **p<0.01 and ***p<0.001 vs. control chow, #p<0.05, ##p<0.01 and ###p<0.001 HFCC+CDX vs. HFCC

**ULTRA-FAST NASH DIET (HFCC+CDX) PROMOTES LIVER LIPIDS ACCUMULATION, INFLAMMATION AND FIBROSIS**

- Ultra-fast NASH diet promotes liver lipids accumulation, inflammation and fibrosis.
- Ezetimibe reduces hyperlipidemia and improves NAS scoring through reduced inflammation.
- Liraglutide improves NAS scoring by reducing inflammation, independently from lipid lowering.

*PHYSIOGENEX SAS - Prologue Biotech – 516 Rue Pierre et Marie Curie –31670 Labège Cedex – France Phone: +33 561 287 040 - business@physiogenex.com www.physiogenex.com*